HEMGENIX DIN 02542560
Status: Marketed
Holder: CSL BEHRING CANADA INC
Health Canada record
| Active ingredient(s) | ETRANACOGENE DEZAPARVOVEC 10000000000000 GENOME COPIES |
|---|---|
| Dosage form | Suspension |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | B02BD16 ETRANACOGENE DEZAPARVOVEC |
| Original market date | 13-May-2026 |
| Current status date | 13-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
CSL Behring Canada Inc. — licence 101328, currently licensed, last inspection rating C (2026-01-13).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31923 | 2023-10-23 | New Drug Submission (NDS) |